PARIS – Affluent Medical SA recently raised $17.8 million in new financing. This will be used to bring forward the clinical program for its minimally invasive implants, designed to restore physiological function in patients suffering from structural heart disease as well as urinary incontinence.
Robust financial markets continue to fuel the industry despite gloom over the COVID-19 pandemic, with Relay Therapeutics Inc. pricing its upsized, 20 million-share IPO at $20 per unit to reap $400 million.
Courtesy of a $50 million series A, Adagio Therapeutics Inc. will join a raft of other companies attempting to end the COVID-19 pandemic with antibodies.
Glympse Bio has closed an oversubscribed $46.7 million series B financing, with an eye toward boosting its novel biosensor platform in fibrotic diseases, including nonalcoholic steatohepatitis (NASH), oncology and infectious diseases.
At about $35.6 billion raised by med-tech companies, the first half of 2020 has already pulled in more than the full-year totals for 2017 and 2018 and is at about 87% of what was raised in 2019. Most of the money is coming through private financings of public companies, including large notes offerings and private placements, as well as follow-on offerings.
HONG KONG – Chinese eye disease specialist Arctic Vision (Shanghai) Biotechnology Co. Ltd. raised $32 million in a series A financing round to advance its lead program, ARVN-001 (triamcinolone acetonide suprachoroidal injectable suspension), for treating macular edema associated with uveitis and to bolster its R&D.
RSS
